Juvenile Ocular Myasthenia Gravis: Presentation and Outcome of a Large Cohort

Vanikieti, Kavin; Lowwongngam, Kasamon; Padungkiatsagul, Tanyatuth; Visudtibhan, Anannit; Poonyathalang, Anuchit

doi:10.1016/j.pediatrneurol.2018.06.007

Cited by 27 publications

(41 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among numerous studies have investigated oral drug therapy for OMG, few have examined strabismus, ptosis, or quantified measurements of the range of eye movement as outcomes [ 6 , 18 , 19 ]. Kupersmith et al [ 18 ] reported on the use of prednisone and pyridostigmine for the treatment of patients with OMG.…”

Section: Discussionmentioning

confidence: 99%

“…Six cases underwent strabismus surgery. Vanikieti et al [ 6 ] performed a retrospective study of the effect of oral prednisone and/or pyridostigmine for OMG in children. Only 13 (21.67%) of 60 children with blepharoptosis achieved drug-independent remission, and only 3 (7.9%) of 38 patients with ophthalmoplegia achieved drug-independent remission.…”

Section: Discussionmentioning

confidence: 99%

“…About 60% MG known as simple OMG [ 3 – 5 ]. This proportion is higher among children, reaching 71 to 93% [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Local use of dexamethasone in the treatment of ocular myasthenia gravis

Shi

Zhou

et al. 2020

BMC Ophthalmol

View full text Add to dashboard Cite

Background At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4–6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months. Results Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period. Conclusions Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy. Trial registration Chinese Clinical Trial Registry, ChiCTR2000038863, October 7, 2020.Retrospectively registered.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Local use of dexamethasone in the treatment of ocular myasthenia gravis

Shi

Zhou

et al. 2020

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…We sought to identify the reason for this phenomenon. Nan et al [6,18,19,21] reported that a single sub-Tenon injection of triamcinolone acetonide (TA) was able to diffuse throughout the globe, including the aqueous, irisciliary body, vitreous, neuroretina, retinal pigment epithelium, and choroid, with therapeutic concentrations maintained for at least 30 days. Roesel et al [23] observed similar results for the use of periocular corticosteroid injections, administered via the sub-Tenon route or as an orbital oor injection, for the treatment of uveitis.…”

Section: Discussionmentioning

confidence: 99%

“…About 60% MG known as simple OMG [3][4][5].This proportion is higher among children, reaching 71% to 93%. [5,6] In the past, even patients with OMG in whom symptoms were limited to the eyes were treated with systemic drugs, including acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, immunomodulating agents and, recently, vascular growth factor inhibitors [7][8][9]. Among these treatments, oral acetylcholinesterase inhibitors and corticosteroids were used most commonly [7][8][9].few patients underwent thymectomy or other types of surgery [10].…”

Section: Introductionmentioning

confidence: 99%

Local Use of Dexamethasone in the Treatment of Ocular Myasthenia Gravis

Shi

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods: Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4-6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months. Results: Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period.Conclusions: Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy.

show abstract

Myasthenia Gravis

Carey¹

2021

Controversies in Neuro-Ophthalmic Management

View full text Add to dashboard Cite

Juvenile Ocular Myasthenia Gravis: Presentation and Outcome of a Large Cohort

Cited by 27 publications

References 17 publications

Local use of dexamethasone in the treatment of ocular myasthenia gravis

Local use of dexamethasone in the treatment of ocular myasthenia gravis

Local Use of Dexamethasone in the Treatment of Ocular Myasthenia Gravis

Myasthenia Gravis

Contact Info

Product

Resources

About